RT Bloomberg em Português (@BBGEmPortugues)O Fortitude Capital, fundo de private equity com aporte do BTG Pactual, já captou quase 500 milhões de euros para investir em estádios de futebol em Portugal https://t.co/ecNQERSt3p ...

Group 1 - The core viewpoint of the article is the establishment of the Zhongjin Yaosheng Mother Fund, which aims to leverage state-owned capital to promote the development of strategic emerging industries and achieve a win-win situation for industrial development and investment returns [1] - The Zhongjin Yaosheng Mother Fund has a total scale of 5 billion RMB and is focused on industries encouraged by the Shangyu district, including semiconductors, new materials, advanced manufacturing, medical and pharmaceutical, artificial intelligence, and new consumption [1] - The fund is open to soliciting high-quality sub-fund management institutions without restrictions on the registration location of the sub-funds [2]

Sean, thanks for coming back on the program. And I see you brought two of your partners in crime. I am curious about just how far you want to take Harbinger Sports and and whether the moment that we're in right now with all of the attention on alternative investing and specifically investing in sports league franchises, teams, if that is providing the opportunity going forward.Yeah, 100%. I think there is a huge opportunity. There are kind of three things happening at the same time.One, there is this macro ...

Core Insights - ECGI Holdings Inc. has announced that its investment arm, Uplist Ventures, has become an affiliate member of TCA Venture Group, enhancing its access to a prominent angel investor network in the U.S. [1][4] - TCA Venture Group has invested over $280 million in 545 companies, which have collectively attracted an additional $2.1 billion in follow-on funding and achieved 126 exits, including 17 public listings [2] - The affiliation allows Uplist Ventures to access a curated pipeline of investment opportunities typically reserved for institutional investors, focusing on Series A and B startups [3][4] Company Strategy - The partnership with TCA is part of ECGI's strategy to align with respected players in the venture community, aiming to identify high-growth potential companies and explore pathways for future IPOs [4] - Uplist Ventures emphasizes disciplined growth and aims to strengthen its credibility within the venture and capital markets ecosystem [4] Investment Focus - ECGI, through Uplist Ventures, targets early-stage startups in sectors such as artificial intelligence, healthcare technology, blockchain, and vertical software [5] - Current investments include: - Payday Fantasy, which operates in the $89.9 billion global fantasy sports market [6] - TrueToForm, a patented AI-powered 3D body measurement SaaS in the $8.2 billion apparel fitting market [7] - Pacific Saddlery, a manufacturer in the $6.5 billion equestrian apparel market and the $11 billion equestrian equipment market [7] - Vintner's Caldera Ranch, a vineyard tapping into the $121 billion short-term rental market [8]

Private equity firms struggling to realize returns for their investors are likely to offer an opportunity for distressed debt investors, according to Glendon Capital co-founder Holly Kim https://t.co/NZ4mPWWE7c ...

文：韦亚军 新加坡曹宝记（TPC）集团通过在华平台曹宝记（中国）企业管理有限公司出资0.6亿元，占14.63%， 为第二大LP。 施罗德资本则通过旗下海南三亚施罗德股权投资基金合伙企业（有限合伙）出资0.23亿元，占5.58%，为第三大LP。 通过出资结构，我们可以看出这是典型的"外资GP+境内机构LP"组合。 在过去的2年里，放眼中国一级市场，除了KKR，其他几乎能够叫得出名字的全球PE巨头，包括华平投资、汉领资本（Hamilton Lane）、路威凯腾（L Catterton）、施罗德资本、亚赋资本（Affirma Capital）、博枫（Brookfield）、以及黑石、凯雷、CVC等，都已经募集过或正在募集人民币基金。 摄影：Bob君 募集人民币基金，已经成为跨国PE们的新共识。 近日，KKR境内管理实体开德时璞（上海）私募投资基金合伙企业（有限合伙）在中国证券投资基金业协会完成备案，基金类型为私募股权基金。这标 志着KKR首支在岸人民币基金正式落地。 开德时璞成立于2024年12月，注册地在上海浦东，由KKR香港公司100%控股。 其中，平安资本通过旗下母基平台——金嘉兴平汇利海股权投资合伙企业（有 ...

L Catterton, the private equity firm backed by French billionaire Bernard Arnault, led a $800 million equity investment in Flexjet, as demand for private jet travel around the world continues to surge https://t.co/nakbasV8pf ...

Core Insights - Lantheus (NASDAQ: LNTH) stock experienced a significant decline from $108 to $80 between January and May 2025, indicating volatility in its performance [1] Company Overview - MMMT Wealth, founded by Oliver, focuses on investment strategies and stock analysis, primarily in private equity, hedge funds, and asset management [1] - Oliver has 5 years of investing experience and 4 years as a CPA, emphasizing a long-term investment horizon of 3-5 years [1] Investment Philosophy - The company aims to gather insights from various sources, including investor calls, presentations, and financial reports, to form informed opinions on stocks [1] - Oliver's passion for investing is highlighted, with a belief that even a few successful investments can be life-changing [1]

Transaction Overview - CVC Capital Partners initiates refinancing of its sports assets portfolio [1] - The portfolio is valued at over £9 billion, equivalent to $12 billion [1]

Core Insights - Royalty Pharma plc has appointed Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, enhancing its leadership team with expertise in biopharmaceuticals and finance [1][2][3] Group 1: Board Appointments - Carole Ho is the Chief Medical Officer and Head of Development at Denali Therapeutics, with 20 years of experience in biopharma, previously serving as Vice President of Clinical Development at Genentech [2][3] - Bess Weatherman has 35 years of experience as an investor in the healthcare industry and is currently a Special Limited Partner at Warburg Pincus, having joined the firm in 1988 [3] Group 2: Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical sector, collaborating with various innovators [4] - The company has a portfolio that includes royalties on over 35 commercial products and 16 development-stage product candidates, indicating a strong position in the market [4] Group 3: Corporate Governance - The appointment of the new board members increases independent representation on the board to over 90%, reflecting Royalty Pharma's commitment to enhanced corporate governance [5]